Rilonacept granted Orphan Drug designation in the US for the treatment of pericarditis

Rilonacept is a recombinant fusion protein that blocks interleukin-1 alpha and interleukin-1 beta signalling. The company recently announced that it met the prespecified primary endpoints in the Phase III RHAPSODY study in recurrent pericarditis.


Biospace Inc.